AstraZeneca (AZN.US)/ Daiichi Sankyo's ADC First-line Treatment for Lung Cancer Phase III Study Success

According to Zhito Finance APP, on August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (fam-trastuzumab deruxtecan) monotherapy as a first-line treatment for non-small cell lung cancer (NSCLC) achieved highly positive results.